Understand the importance of biomarkers in the management of your patients with NSCLC
of patients like yours may harbor METex14 skipping1–4
testing can accurately detect METex14 skipping, and is encouraged by global guidelines5–7
Up to 4% of patients like yours are living with a METex14 skipping subtype alteration associated with poor prognosis.1–4 A study assessing the overall survival in patients with METex14 skipping NSCLC demonstrated that those who harbor this alteration have a significantly shorter OS compared to those without.8
Having a choice of biopsies could offer both reliability and flexibility in your testing approach.6
Tissue biopsies are considered the gold standard approach to diagnosis of NSCLC, but there is an increasing uptake of non-invasive approaches in biomarker testing in clinical practice.6
Liquid biopsies offer the ability to monitor a patient’s response to therapy and identify resistance mutations in patients without the need for repeat tissue biopsies.6
Liquid biopsies involve the analysis of circulating tumor DNA in the plasma and can provide flexibility and ease of access.6 Concordance between tissue and liquid tumor biopsies has been shown to be >90%, positioning liquid biopsies as an important yet underutilized
tool in NSCLC.8
There are multiple platforms that can be used to test for gene mutations, including IHC, FISH, RT-PCR and NGS.
Of these, NGS is the most frequently used diagnostic tool.9 Including METex14 in your liquid or tissue diagnostic panel could help you monitor for alterations in your patients with NSCLC.6
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; OS, overall survival; RT-PCR, reverse transcription polymerase chain reaction
1. Salgia R. Mol Cancer Ther 2017; 16:555–565.
2. Ikeda S et al. J Hematol Oncol 2018; 11:76.
3. Wang Q et al. J Hematol Oncol 2019; 12:63.
4. Sterlacci W et al. Virchows Arch 2017; 471:49–55.
5. Kim EK et al. Clin Lung Cancer 2019; 20:e123–e132.
6. Pennell NA et al. Am Soc Clin Oncol Edu Book 2019; 39(531–542).
7. Chen M, Zhao H. Hum Genomics 2019; 13:34.
8. Tong JH et al. Clin Cancer Res 2016; 22:3048–3056.
9. Kamps R et al. Int J Mol Sci 2017; 18:308.
10. Qi ZH et al. J Cancer 2018; 9:3417–3426.